TNF Pharmaceuticals (NASDAQ:TNFA – Get Free Report) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research report issued on Friday.
TNF Pharmaceuticals Stock Down 8.6%
TNF Pharmaceuticals stock opened at $3.30 on Friday. The business has a 50 day moving average price of $9.96 and a two-hundred day moving average price of $21.10. The stock has a market cap of $5.91 million, a price-to-earnings ratio of -0.01 and a beta of 2.04. TNF Pharmaceuticals has a 12 month low of $3.24 and a 12 month high of $195.00.
TNF Pharmaceuticals (NASDAQ:TNFA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 19th. The company reported ($18.00) EPS for the quarter.
TNF Pharmaceuticals Company Profile
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.
Further Reading
- Five stocks we like better than TNF Pharmaceuticals
- The Basics of Support and Resistance
- Spire Global: Tiny Satellites, Big Buy Ratings and Upside
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Energy Fuels: Is This America’s Most Strategic Stock?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Silver and Gold Break Out—3 Names to Ride The Wave
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
